Edgar Filing: Viallet Jean - Form 4

Viallet Jean Form 4										
April 05, 2013										
FORM	4								PPROVAL	
Washington, D.C. 20549									3235-0287	
Check this box if no longer								Expires:	January 31, 2005	
subject to Section 16. Form 4 or							Estimated burden hou response	average urs per		
Form 5 obligations may continu <i>See</i> Instructi 1(b).	e. Section 17	(a) of the	Public U	Jtility Ho	olding Co		inge Act of 1934, t of 1935 or Secti 1940			
(Print or Type Res	ponses)									
1. Name and Address of Reporting Person <u>*</u> Viallet Jean			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer				
	CLEVELAND BIOLABS INC [CBLI]					(Check all applicable)				
(Last) (First) (Middle) C/O CLEVELAND BIOLABS,			3. Date of Earliest Transaction (Month/Day/Year) 04/03/2013			Director 10% Owner X Officer (give title Other (specify below) below) Chief Development Officer				
INC., 73 HIGH							Chiler I	Development Of	ncei	
	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
BUFFALO, N	Y 14203						Person	whole than one it	eporting	
(City)	(State)	(Zip)	Tał	ole I - Non	-Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date any (Month/Day/Year)		Date, if	Code	4. Securi onAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price				
Reminder: Report	on a separate line	e for each cl	ass of sec	urities ben	-	-	-			
					inforı requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ently valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	Beneficially Owned securities)	d		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Viallet Jean - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	ed (A) or ed of (D)		(Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 2.04	04/03/2013		А	100,000		<u>(1)</u>	04/03/2023	Common Stock	100,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Viallet Jean C/O CLEVELAND BIOLABS, INC. 73 HIGH STREET BUFFALO, NY 14203			Chief Development	Officer			
Signatures							
/s/ Leah Brownlee, Attorney-in-fact fo Viallet	or Jean	04	4/05/2013				

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option becomes exercisable in four equal installments on the following dates: April 4, 2013, April 1, 2014, April 1, 2015 and April 1, 2016. 25,000 shares underlying the option are currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.